TY  - JOUR
AU  - Fraile-Ribot, Pablo A.
AU  - Zamorano, Laura
AU  - Orellana, Rocio
AU  - Del Barrio-Tofiño, Ester
AU  - Sanchez-Diener, Irina
AU  - Cortes-Lara, Sara
AU  - Lopez-Causape, Carla
AU  - Cabot, Gabriel
AU  - Bou, German
AU  - Martinez-Martinez, Luis
AU  - Oliver, Antonio
PY  - 2019
DO  - 10.1128/AAC.02165-19
UR  - http://hdl.handle.net/10668/14708
T2  - Antimicrobial Agents and Chemotherapy
AB  - Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the...
LA  - en
PB  - ASM Journals
KW  - Pseudomonas aeruginosa
KW  - Antibiotic resistance
KW  - Extensively drug resistant
KW  - Imipenem-relebactam
KW  - Multidrug resistance
KW  - Whole-genome sequencing
KW  - β-lactam resistance mechanisms
KW  - Anti-Bacterial agents
KW  - Azabicyclo compounds
KW  - Colistin
KW  - Humans
KW  - Imipenem
KW  - Mutation
KW  - Pseudomonas infections
KW  - Pseudomonas aeruginosa
KW  - beta-Lactam Resistance
KW  - beta-Lactamases
TI  - Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
TY  - research article
VL  - 64
ER  -